Category Archives: Myocardial Infarction

COVID-19 vaccination provides individuals with a reduced risk of experiencing an acute myocardial infarction or ischaemic stroke after becoming infected with the virus according to the findings of a study by Korean researchers. It has now become recognised that following an acute infection with COVID-19, beyond the first 30 days, individuals with COVID-19 have an increased risk of cardiovascular disease and which includes cerebrovascular disorders, dysrhythmias, ischaemic and non-ischaemic heart disease, pericarditis, myocarditis, heart failure and thromboembolic disease. While it is clear that a COVID-19 vaccination is safe and offers protection against severe COVID-19, hospitalisation and death against all current variants of concern, what is less clear is whether vaccination is able to reduce the post-infection cardiovascular sequelae Continue reading →

Objectives The primary goal of this study is to explore demographic and comorbid factors that increase the hospitalization risk of acute myocardial infarction (AMI) in patients with vasculitis along with the utilization rate of percutaneous coronary intervention (PCI)/angioplasty. Additionally, we aim to study the prevalence of AMI in vasculitis inpatients based on geographical distribution Continue reading →

For a study, researchers sought to examine whether using 4% albumin solution instead of Ringer acetate as the cardiopulmonary bypass prime solution and the perioperative intravenous volume replacement solution lowered the incidence of significant perioperative and postoperative complications in patients having cardiac surgery. Patients undergoing on-pump coronary artery bypass grafting, aortic, mitral, or tricuspid valve surgery, ascending aorta surgery without hypothermic circulatory arrest, and/or the maze procedure were randomly assigned to 2 study groups in a randomized, double-blind, single-center clinical trial from 2017 to 2020 at a tertiary university hospital (the last follow-up was April 13, 2020). Continue reading →

Early improvement of left ventricular ejection fraction (LVEF) after transcatheter aortic valve replacement (TAVR) is associated with improved all-cause and cardiac death at 5 years in patients with severe aortic stenosis and LVEF less than 50%, new research shows. Further analyses also revealed a significant interaction by sex, with the mortality benefit largely in women Continue reading →

1. Amongst patients with gout, those who experienced a cardiovascular event were likely to have recently experienced a preceding gout flare Continue reading →

TUESDAY, Aug. 9, 2022 (HealthDay News) -- The presence of hypertension is associated with an increased risk for hospitalization for omicron infection among individuals who received at least three mRNA COVID-19 vaccine doses, according to a research letter published online July 20 in Hypertension. Joseph Ebinger, M.D., from the Cedars Sinai Medical Center in Los Angeles, and colleagues examined the characteristics associated with severe omicron infection necessitating hospitalization, despite receipt of three doses of an mRNA vaccine in a retrospective cohort study. Continue reading →

The following article was written by Dr. Alaa Diab as a CardioNerds Conference Scholar for The American Society for Preventive Cardiology 2022 Congress on Cardiovascular Disease Prevention. Type 2 diabetes mellitus is becoming more prevalent in the United States, with an estimate of 37.3 million Americans living with diabetes according to the 2020 CDC statistics. Continue reading →

Current Opinion in Endocrinology & Diabetes and Obesity: August 05, 2022 - Volume - Issue - 10.1097/MED.0000000000000764 .. there are things we know we know Continue reading →

Collaboration NCDRF. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet Continue reading →

Evolve Business Intelligence published a new market research report on Global Cardiac Biomarkers Market by Product Type (Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Troponins (T and I), Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), and Others), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), by Location of Testing (Laboratory testing and Point of Care Testing) and By Geography COVID-19 Impact Analysis, Post COVID Analysis, Opportunities, Trends, and Forecast from 2022 to 2032 The global Cardiac Biomarkers market Size Is Expected To Grow At A CAGR Of Approx. 12% From 2022 To 2032. The Cardiac Biomarkers Market report provides data on industry size and growth rate, globally and by region. Continue reading →